Patent Cliff Hits: India, China & Brazil Unlock Cheap Semaglutide – Hims & Hers Poised to Dominate Globally!

Shernice軒嬣 2000

Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming!

$Hims & Hers Health Inc.(HIMS)$

Here's why this could be a game-changer for Hims & Hers (and patients worldwide):

Lower Costs

As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims & Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion

Hims & Hers is already pushing internationally (just entered Canada!). With cheap, legal generics in 150+ countries, they can roll out weight-loss programs globally – no more US patent headaches holding them back.

Diversified Options

"Branded generics" will flood the market. Hims & Hers already offers a compounded semaglutide pill (needle-free for those who hate injections!). Mass-produced generic pills will make even more affordable, just-as-effective oral options available. The future of weight loss just got a lot more accessible and exciting!

@Tiger_comments @Daily_Discussion @TigerStars @TigerObserver @TigerPM

💰Stocks to watch today?(24 Mar）

1. What news/movements are worth noting in the market today? Any stocks to watch? 2. What trading opportunities are there? Do you have any plans? 🎁 Make a post here, everyone stands a chance to win Tiger coins!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

3

1

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":539763565827128,"tweetId":"539763565827128","gmtCreate":1772799778751,"gmtModify":1773047809004,"author":{"id":3560184106659134,"idStr":"3560184106659134","authorId":3560184106659134,"authorIdStr":"3560184106659134","name":"Shernice軒嬣 2000","avatar":"https://community-static.tradeup.com/news/6eb28f05fb053c58e617cac286725dc1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.30","individualDisplayEnabled":0},"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.03.23","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":2281,"starInvestorFlag":false},"themes":[{"themeId":"470d3ab575ca43caaed8156645b7ccbe","categoryId":"ab3d937a5fd848c08008411a9be702b5","name":"💰Stocks to watch today?(24 Mar）","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":470d3ab575ca43caaed8156645b7ccbe}&rnconfig={\"headerBarHidden\": true}","description":"1. What news/movements are worth noting in the market today? Any stocks to watch? \n2. What trading opportunities are there? Do you have any plans?\n🎁 Make a post here, everyone stands a chance to win Tiger coins!","image":"https://static.tigerbbs.com/cd8eaff2e99964ab7a80d92cc196fcd3"}],"images":[{"img":"https://community-static.tradeup.com/news/1b57f84a6f06a42d97f86453c83871e5","width":"1079","height":"1248"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/1b57f84a6f06a42d97f86453c83871e5","width":"1079","height":"1248"}],"title":"Patent Cliff Hits: India, China & Brazil Unlock Cheap Semaglutide – Hims & Hers Poised to Dominate Globally!","html":"<html><head></head><body><p>Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming!&nbsp;</p>\n<p><a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a>&nbsp;</p>\n<p class=\"t-img-caption\" style=\"display: flex; flex-direction: column; align-items: center;\"><img src=\"https://community-static.tradeup.com/news/1b57f84a6f06a42d97f86453c83871e5\" tg-width=\"1079\" tg-height=\"1248\"><span></span></p>\n<p>&nbsp;Here's why this could be a game-changer for Hims &amp; Hers (and patients worldwide):&nbsp;</p>\n<h3>&nbsp;Lower Costs</h3>\n<p>As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims &amp; Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion</p>\n<p>Hims &amp; Hers is already pushing internationally (just entered Canada!). With cheap, legal generics in 150+ countries, they can roll out weight-loss programs globally – no more US patent headaches holding them back.</p>\n<h3>&nbsp;Diversified Options</h3>\n<p>\"Branded generics\" will flood the market. Hims &amp; Hers already offers a compounded semaglutide pill (needle-free for those who hate injections!). Mass-produced generic pills will make even more affordable, just-as-effective oral options available. The future of weight loss just got a lot more accessible and exciting!</p>\n<p><a href=\"https://ttm.financial/U/3501196737273098\">@Tiger_comments </a>&nbsp;<a href=\"https://ttm.financial/U/3527667621665671\">@Daily_Discussion </a>&nbsp;<a href=\"https://ttm.financial/U/9000000000000149\">@TigerStars </a>&nbsp;<a href=\"https://ttm.financial/U/9000000000000439\">@TigerObserver </a>&nbsp;<a href=\"https://ttm.financial/U/3527667588142897\">@TigerPM </a>&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming!&nbsp;</p>\n<p><a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a>&nbsp;</p>\n<p class=\"t-img-caption\" style=\"display: flex; flex-direction: column; align-items: center;\"><img src=\"https://community-static.tradeup.com/news/1b57f84a6f06a42d97f86453c83871e5\" tg-width=\"1079\" tg-height=\"1248\"><span></span></p>\n<p>&nbsp;Here's why this could be a game-changer for Hims &amp; Hers (and patients worldwide):&nbsp;</p>\n<h3>&nbsp;Lower Costs</h3>\n<p>As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims &amp; Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion</p>\n<p>Hims &amp; Hers is already pushing internationally (just entered Canada!). With cheap, legal generics in 150+ countries, they can roll out weight-loss programs globally – no more US patent headaches holding them back.</p>\n<h3>&nbsp;Diversified Options</h3>\n<p>\"Branded generics\" will flood the market. Hims &amp; Hers already offers a compounded semaglutide pill (needle-free for those who hate injections!). Mass-produced generic pills will make even more affordable, just-as-effective oral options available. The future of weight loss just got a lot more accessible and exciting!</p>\n<p><a href=\"https://ttm.financial/U/3501196737273098\">@Tiger_comments </a>&nbsp;<a href=\"https://ttm.financial/U/3527667621665671\">@Daily_Discussion </a>&nbsp;<a href=\"https://ttm.financial/U/9000000000000149\">@TigerStars </a>&nbsp;<a href=\"https://ttm.financial/U/9000000000000439\">@TigerObserver </a>&nbsp;<a href=\"https://ttm.financial/U/3527667588142897\">@TigerPM </a>&nbsp;</p></body></html>","text":"Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming! $Hims & Hers Health Inc.(HIMS)$ Here's why this could be a game-changer for Hims & Hers (and patients worldwide): Lower Costs As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims & Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion Hims & Hers is already pushing internationally (just entered Canada!). With cheap, legal generics in 150+ countries, they can roll out weight-loss programs globally – no more US patent headaches holding them back. Diversified Options \"Branded generics\" will flood the market. Hims & Hers already offers a compounded semaglutide pill (needle-free for those who hate injections!). Mass-produced generic pills will make even more affordable, just-as-effective oral options available. The future of weight loss just got a lot more accessible and exciting! @Tiger_comments @Daily_Discussion @TigerStars @TigerObserver @TigerPM","highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":0,"repostSize":1,"favoriteSize":0,"link":"https://ttm.financial/post/539763565827128","repostId":0,"isVote":1,"tweetType":1,"viewCount":760,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["HIMS"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1053,"optionInvolvedFlag":true,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/539763565827128"}